Eric S. Groves

1.3k total citations
26 papers, 1.0k citations indexed

About

Eric S. Groves is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Eric S. Groves has authored 26 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology, 9 papers in Oncology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Eric S. Groves's work include Toxin Mechanisms and Immunotoxins (7 papers), Immunotherapy and Immune Responses (6 papers) and CAR-T cell therapy research (5 papers). Eric S. Groves is often cited by papers focused on Toxin Mechanisms and Immunotoxins (7 papers), Immunotherapy and Immune Responses (6 papers) and CAR-T cell therapy research (5 papers). Eric S. Groves collaborates with scholars based in United States, Switzerland and Australia. Eric S. Groves's co-authors include Alfred Singer, Michael Konrad, Mark Holodniy, David Katzenstein, Su Yeon Kim, T. C. Merigan, Louis M. Weiner, Arthur E. Frankel, Denis L. Jardim and Philip P. Breitfeld and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Eric S. Groves

26 papers receiving 996 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric S. Groves United States 16 441 247 235 205 143 26 1.0k
James T. Kurnick United States 24 992 2.2× 451 1.8× 425 1.8× 287 1.4× 86 0.6× 49 1.6k
Patricia C. Ryan United States 19 299 0.7× 495 2.0× 372 1.6× 148 0.7× 110 0.8× 32 1.3k
Søren Bregenholt Denmark 19 504 1.1× 467 1.9× 141 0.6× 212 1.0× 147 1.0× 31 1.3k
P J Morrissey Canada 14 1.0k 2.3× 313 1.3× 236 1.0× 117 0.6× 37 0.3× 16 1.4k
D. Sulitzeanu Israel 17 460 1.0× 301 1.2× 375 1.6× 243 1.2× 46 0.3× 106 1.2k
John T. Kung United States 23 1.1k 2.4× 501 2.0× 347 1.5× 294 1.4× 53 0.4× 58 1.9k
Barbara Boone Belgium 15 423 1.0× 582 2.4× 401 1.7× 123 0.6× 41 0.3× 24 1.6k
Carin E.G. Havenith Netherlands 20 910 2.1× 347 1.4× 343 1.5× 379 1.8× 65 0.5× 33 1.9k
Margaret Nelson Australia 25 604 1.4× 300 1.2× 297 1.3× 125 0.6× 36 0.3× 66 1.5k
Katerina Angelopoulou Greece 20 148 0.3× 255 1.0× 334 1.4× 78 0.4× 105 0.7× 55 936

Countries citing papers authored by Eric S. Groves

Since Specialization
Citations

This map shows the geographic impact of Eric S. Groves's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric S. Groves with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric S. Groves more than expected).

Fields of papers citing papers by Eric S. Groves

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric S. Groves. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric S. Groves. The network helps show where Eric S. Groves may publish in the future.

Co-authorship network of co-authors of Eric S. Groves

This figure shows the co-authorship network connecting the top 25 collaborators of Eric S. Groves. A scholar is included among the top collaborators of Eric S. Groves based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric S. Groves. Eric S. Groves is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jardim, Denis L., Eric S. Groves, Philip P. Breitfeld, & Razelle Kurzrock. (2016). Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. Cancer Treatment Reviews. 52. 12–21. 67 indexed citations
2.
3.
Negro‐Vilar, A., Zofia E. Dziewanowska, Eric S. Groves, et al.. (2007). Efficacy and safety of denileukin diftitox (Dd) in a phase III, double-blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL). Journal of Clinical Oncology. 25(18_suppl). 8026–8026. 15 indexed citations
4.
5.
Rosenthal, M., et al.. (2006). (865). Journal of Pain. 7(4). S67–S67. 1 indexed citations
6.
Lee, Ding‐Jen, Andy Trotti, Sharon A. Spencer, et al.. (1998). Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. International Journal of Radiation Oncology*Biology*Physics. 42(4). 811–815. 64 indexed citations
7.
Laske, Douglas W., Karin M. Muraszko, Edward H. Oldfield, et al.. (1997). Intraventricular Immunotoxin Therapy for Leptomeningeal Neoplasia. Neurosurgery. 41(5). 1039–1051. 62 indexed citations
8.
Lee, Ding‐Jen, Andy Trotti, Sharon A. Spencer, et al.. (1996). 87 A phase II trial of radiotherapy with concurrent tirapazamine, a hypoxic cytotoxin, for advanced head and neck carcinomas. International Journal of Radiation Oncology*Biology*Physics. 36(1). 202–202. 2 indexed citations
9.
Pearson, John W., William E. Fogler, Katharina Völker, et al.. (1993). Restoration of Interferon   Potentiation of a Recombinant Ricin A Chain Immunotoxin Following Cytoreduction of Xenografts of Advanced Ovarian Tumors. JNCI Journal of the National Cancer Institute. 85(11). 907–912. 3 indexed citations
10.
Buckman, Robert, Carlo DeAngelis, Patricia Shaw, et al.. (1992). Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecologic Oncology. 47(1). 102–109. 39 indexed citations
11.
Redman, Bruce G., Ta‐Hsu Chou, Michael Kraut, et al.. (1992). Phase I Trial of Recombinant Macrophage Colony-Stimulating Factor by Rapid Intravenous Infusion in Patients with Cancer. Journal of Immunotherapy. 12(1). 50–54. 18 indexed citations
12.
Zamkoff, Kenneth W., et al.. (1992). A Phase I Trial of Recombinant Human Macrophage Colony-Stimulating Factor by Rapid Intravenous Infusion in Patients with Refractory Malignancy. Journal of Immunotherapy. 11(2). 103–110. 17 indexed citations
13.
Konrad, Michael, et al.. (1992). Suppression and transient induction of lymphokines in cancer patients after administration of polyethylene glycolated interleukin‐2. European Journal of Immunology. 22(3). 727–733. 5 indexed citations
14.
Sanda, Marie, Eric S. Groves, Rubens Belfort, et al.. (1992). Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study.. Journal of Clinical Oncology. 10(10). 1643–1649. 18 indexed citations
15.
Holodniy, Mark, Su Yeon Kim, David Katzenstein, et al.. (1991). Inhibition of human immunodeficiency virus gene amplification by heparin. Journal of Clinical Microbiology. 29(4). 676–679. 159 indexed citations
16.
Pearson, John W., Erik Hedrick, William E. Fogler, et al.. (1990). Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon.. PubMed. 50(19). 6379–88. 19 indexed citations
17.
Gould, B J, Michael J. Borowitz, Eric S. Groves, et al.. (1989). Phase I Study of an Anti-Breast Cancer Immunotoxin by Continuous Infusion: Report of a Targeted Toxic Effect Not Predicted by Animal Studies. JNCI Journal of the National Cancer Institute. 81(10). 775–781. 93 indexed citations
18.
Bookman, Michael A., Eric S. Groves, & L A Matis. (1986). Expression of MEL-14 antigen is not an absolute requirement for dissemination to lymph nodes after adoptive transfer of murine T lymphocyte clones.. The Journal of Immunology. 137(7). 2107–2114. 8 indexed citations
19.
20.
Groves, Eric S. & Alfred Singer. (1983). Role of the H-2 complex in the induction of T cell tolerance to self minor histocompatibility antigens.. The Journal of Experimental Medicine. 158(5). 1483–1497. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James T. Kurnick Breakdown of academic impact, for papers by Patricia C. Ryan Breakdown of academic impact, for papers by Søren Bregenholt Breakdown of academic impact, for papers by P J Morrissey Breakdown of academic impact, for papers by D. Sulitzeanu Breakdown of academic impact, for papers by John T. Kung Breakdown of academic impact, for papers by Barbara Boone Breakdown of academic impact, for papers by Carin E.G. Havenith Breakdown of academic impact, for papers by Margaret Nelson Breakdown of academic impact, for papers by Katerina Angelopoulou
Rankless by CCL
2026